Iovance Biotherapeutics, Inc. revenue breakdown overview

Iovance Biotherapeutics, Inc. revenue for the last year amounted to 164.07 M USD, the most of which — 164.07 M USD — came from its highest performing source at the moment, Autologous Tumor Infiltrating Lymphocyte Cell Therapies, the year earlier bringing 1.19 M USD. The greatest contribution to the revenue figure was made by United States — last year it brought Iovance Biotherapeutics, Inc. 161.04 M USD, and the year before that — 1.19 M USD.